The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Holding a dose indefinitely: is there a documented downside?

This is a generated summary. It shows the 5 most-liked posts from a topic of 33, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
MP
mira.patelTL4 Admin28 Jan 2025 · edited#8
peak_purity, post #4: Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter… Go to post

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

24 likes in reply to #4 18mo
SL
s.leclercTL4 Moderator4 Mar 2025#12
h.falk, post #1: Holding a dose indefinitely: is there a documented downside? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about technique rather than about dose. I have been doing the same thing for 6 months and it works, and then I read one of the documentation pages here and realised I may have… Go to post

Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that stepping down is followed by some regain, with the magnitude unknown.

32 likes in reply to #1 17mo
MC
m.coelhoTL2 Moderator27 Apr 2025#19

I read post #17 twice before replying, because I had assumed the opposite.

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

33 likes 15mo
KA
k.agyemanTL2 Moderator27 May 2025#23

How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used slightly different ones. Reading them side by side shows the variation is real but small.

32 likes 14mo
NS
no.silvaTL2 Moderator27 Jul 2025#32

Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that stepping down is followed by some regain, with the magnitude unknown.

27 likes 12mo

Read the full topic (33 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Revisiting: The arithmetic of an intermediate dose between two label steps
Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
CSRHGBWTMR+41 45 808 2mo
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking…
KVBVHDITNL+14 18 1.2k 13mo
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I…
CCNWVNRW+56 60 21k 2y
Coming back to: Where the four-week escalation interval comes from, and what it is not
Posting this under the heading it deserves: Where the four-week escalation interval comes from, and what it is not Everything below is what sits behind that. I have read the maintained page on this and I…
AKPIHISSFF+44 48 11k 1d
Why "dose equivalence" between different incretin analogues is a weak concept
Why "dose equivalence" between different incretin analogues is a weak concept I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this…
WVERFYWMB+124 133 11k 5mo

Related topics — sharing the tags dose reduction, missed dose, semaglutide

TopicParticipantsRepliesViewsActivity
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking…
KVBVHDITNL+14 18 1.2k 13mo
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
RFNRHC 2 763 15mo
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
SGBCTNNATT+22 26 1.8k 9mo
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? A question about technique rather than about dose. I have been…
MAEKSS 2 8.9k 9mo
Drawing from a pen cartridge with a syringe: how the risk profile changes
Posting this under the heading it deserves: Drawing from a pen cartridge with a syringe: how the risk profile changes Everything below is what sits behind that. I have read the maintained page on this and I…
IDWSR 2 159 19mo